[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.173.230. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Correction
March 21, 2007

Omission of Text in Financial Disclosures in: Tolterodine and Tamsulosin for Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder: A Randomized Controlled Trial

JAMA. 2007;297(11):1195. doi:10.1001/jama.297.11.1195

Omission of Text in Financial Disclosures: In the Original Contribution entitled “Tolterodine and Tamsulosin for Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder: A Randomized Controlled Trial” published in the November 15, 2006, issue of JAMA (2006;296:2319-2328), text in 2 sentences of the financial disclosure was inadvertently omitted. The sentence that read “Dr Roehrborn is also a consultant for GlaxoSmithKline, Sanofi Aventis, and Lilly ICOS, a consultant for Allergan and Esprit, a speaker for Astellas and Esprit, and a study investigator for Allergan and Q-Med” should have read “Dr Roehrborn is also a consultant for GlaxoSmithKline, Sanofi Aventis, and Lilly ICOS, and is a study investigator for Lilly ICOS. Dr Rovner is a paid consultant, speaker, meeting participant, and study investigator for Pfizer; a consultant for Allergan and Esprit; a speaker for Astellas and Esprit; and a study investigator for Allergan and Q-Med.”

×